Core Insights - Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is highlighted as an affordable biotech stock with significant investment potential [1] - The company reported fiscal Q2 2025 results with total revenue of approximately $101.7 million, which includes net product sales of $58.9 million and contract revenues of $42.7 million [2] - Rigel generated a net income of $59.6 million during the same quarter [2] Analyst Ratings - Jefferies analyst Eun Yang maintained a Hold rating on Rigel with a price target of $23.00 [2] - H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating with a price target of $57.00 [2] - Citi also maintained a Buy rating with a price target of $67.00 [3] Company Overview - Rigel Pharmaceuticals is a clinical-stage biotechnology company focused on discovering and developing targeted drugs in oncology, immunology, and immune oncology [3] - The company's product portfolio includes Tavalisse, Fostamatinib, and R835 [3]